PD-1 and PD-L1 expression in NSCLC indicate a favorable prognosis in defined subgroups

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Schmidt, Lars Henning ^a   Kümmel, Andreas ^b   Görlich, Dennis ^c   Mohr, Michael ^a   Bröckling, Sebastian ^a   Mikesch, Jan Henrik ^a   Grünewald, Inga ^d   Marra, Alessandro ^e   Schultheis, Anne M ^f   Wardelmann, Eva ^d   Müller Tidow, Carsten ^g   Spieker, Tilmann ^h   Schliemann, Christoph ^a   Berdel, Wolfgang E ^a   Wiewrodt, Rainer ^a   Hartmann, Wolfgang ^d  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e KLINIKUM BREMEN OST   (Germany)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^h ST FRANZISKUS HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN BCL XL; CD274 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN; TUMOR MARKER;

AGED; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PREDICTIVE VALUE; PROTEIN EXPRESSION; SQUAMOUS CELL LUNG CARCINOMA; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR VOLUME; ADENOCARCINOMA; CANCER GRADING; CANCER STAGING; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; ENZYME IMMUNOASSAY; FOLLOW UP; LUNG NEOPLASMS; METABOLISM; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADENOCARCINOMA; AGED; ANTIGENS, CD274; BIOMARKERS, TUMOR; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84943340055     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0136023     Document Type: Article

References (33)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63(1):11-30. doi: 10.3322/caac.21166 PMID: 23335087
2. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957. doi: 10.1056/NEJMoa0810699 PMID: 19692680
3. Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011;29:2866-2874. doi: 10.1200/JCO.2010.33.4235 PMID: 21670455
4. Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-2394. doi: 10.1056/NEJMoa1214886 PMID: 23724913
5. Hiraoka K, Miyamoto M, Cho Y, Suzuoki M, Oshikiri T, Nakakubo Y, et al. Concurrent infiltration by CD8 + T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 2006;94:275-280. PMID: 16421594
6. Schiller JH, Morgan-Ihrig C, Levitt ML. Concomitant administration of interleukin-2 plus tumor necrosis factor in advanced non-small cell lung cancer. Am J Clin Oncol 1995;18:47-51. PMID: 7847259
7. Jansen RL, Slingerland R, Goey SH, Franks CR, Bolhuis RL, Stoter G. Interleukin-2 and interferonalpha in the treatment of patients with advanced non-small-cell lung cancer. J Immunother 1992;12:70-73. PMID: 1322167
8. Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 2005;25:9543-9553. PMID: 16227604
9. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008;26:677-704. doi: 10.1146/annurev. immunol.26.021607.090331 PMID: 18173375
10. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1 (PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012;24:207-212. doi: 10.1016/j.coi.2011.12.009 PMID: 22236695
11. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, et al. Tumor antigenspecific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009;114:1537-1544. doi: 10.1182/blood-2008-12-195792 PMID: 19423728
12. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004;4:336-347. PMID: 15122199
13. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-2454. doi: 10.1056/NEJMoa1200690 PMID: 22658127
14. Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest 2014;94:107-116. doi: 10.1038/labinvest.2013.130 PMID: 24217091
15. Mu CY, Huang JA, Chen Y, Chen C, Zhang XG. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 2011;28:682-688. doi: 10.1007/s12032-010-9515-2 PMID: 20373055
16. Wimberly H, Brown JR, Schalper K, Haack H, Silver MR, Nixon C, et al. PD-L1 expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer. Cancer Immunol Res 2015;3(4):326-32. doi: 10.1158/2326-6066. CIR-14-0133 PMID: 25527356
17. Schmidt LH, Biesterfeld S, Kümmel A, Faldum A, Sebastian M, Taube C, et al. Tissue microarrays are reliable tools for the clinicopathological characterization of lung cancer tissue. Anticancer Res 2009;29:201-209. PMID: 19331151
18. Schmidt LH, Görlich D, Spieker T, Rohde C, Schuler M, Mohr M, et al. Prognostic impact of Bcl-2 depends on tumor histology and expression of MALAT-1 lncRNA in non-small-cell lung cancer. J Thorac Oncol 2014;9:1294-1304. doi: 10.1097/JTO.0000000000000243 PMID: 25036876
19. D'Incecco A, Andreozzi M, Ludovini V, Rossi E, Capodanno A, Landi L, et al. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer 2015;112(1):95-102. doi: 10.1038/bjc.2014.555 PMID: 25349974
20. Remmele W, Stegner HE. [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe 1987;8(3):138-40. PMID: 33030008
21. Sznol M, Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 2013;19:1021-1034. doi: 10.1158/1078-0432. CCR-12-2063 PMID: 23460533
22. Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 2004;10:5094-5100. PMID: 15297412
23. Chen YB, Mu CY, Huang JA. Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study. Tumori 2012;98:751-755. doi: 10. 1700/1217.13499 PMID: 23389362
24. Boland JM, Kwon ED, Harrington SM, Wampfler JA, Tang H, Yang P, et al. Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung. Clin Lung Cancer 2013;14:157-163. doi: 10.1016/j.cllc.2012.05.006 PMID: 22868219
25. Chen YY, Wang LB, Zhu HL, Li XY, Zhu YP, Yin YL, et al. Relationship betweenprogrammed deathligand 1 and clinicopathological characteristics in non-small cell lung cancer patients. Chin Med Sci J 2013;28:147-151. PMID: 24074616
26. Yang CY, Lin MW, Chang YL, Wu CT, Yang PC. Programmed cell death-ligand1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur J Cancer 2014;50:1361-1369. doi: 10.1016/j.ejca.2014.01.018 PMID: 24548766
27. Sundar R, Soong R, Cho BC, Brahmer JR, Soo RA. Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer 2014;85:101-109. doi: 10.1016/j.lungcan. 2014.05.005 PMID: 24880938
28. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012;4:127ra37. doi: 10.1126/scitranslmed.3003689 PMID: 22461641
29. Droeser RA, Hirt C, Viehl CT, Frey DM, Nebiker C, Huber X, et al. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer 2013;49(9):2233-2242. doi: 10.1016/j. ejca.2013.02.015 PMID: 23478000
30. Schalper KA, Velcheti V, Carvajal D, Wimberly H, Brown J, Pusztai L, et al. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res 2014;20:2773-2782. doi: 10.1158/1078-0432. CCR-13-2702 PMID: 24647569
31. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PDL1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-2465. doi: 10.1056/NEJMoa1200694 PMID: 22658128
32. Soria JC, Cruz C, Bahleda R, Delord JP, Horn L, Herbst RS, et al. Clinical activity, safety and biomarkers of PD-L1 blockade in non-small cell lung cancer (NSCLC): additional analyses from a clinical study of the engineered antibody MPDL3280A (anti-PDL1). Eur J Cancer 2013;49:abstract 3408
33. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018-28. doi: 10.1056/NEJMoa1501824 PMID: 25891174